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Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostaglandin biosynthesis, is
induced by various stimuli including mechanical stress, and plays important roles in
pathophysiological conditions.  For example, gravitational stress has been shown to induce
expression of COX-2 in bone tissues, which is essential for bone homeostasis.  To investigate
whether COX-2 is induced by gravitational loading in other tissues than bone, we exposed mice to
hypergravity at 2G and 3G for 4 hours.  We demonstrate here that COX-2 is induced in the
mouse heart vessels by hypergravity.  Moreover, hypoxia-inducible factor (HIF)-1α and
its downstream genes such as inducible nitric oxide synthase (iNOS), vascular endothelial
growth factor (VEGF) and heme oxygenase (HO)-1 were induced in the heart
simultaneously, while none of these genes were induced in the COX-2 (−/−) mouse heart.
Therefore, COX-2 induced in the heart helps protect the heart function against hypoxia
under hypergravity condition through HIF-1α induction.
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Introduction
Astronauts experience hypergravity of 3.2G at launch and 1.4G on reentry, and
aviators of jet fighters are exposed to accelerated hypergravity.  To prevent unwanted
outcomes by exposure to such an increased gravity, it is helpful to understand the biological
responses to hypergravity using animal models.  It has been well investigated that
mechanical stress caused by the gravity is important to maintain the bone mass, because a
reduced gravity decreases the mass and mechanical properties of human and animal bones
[1].  Prostaglandins (PGs) have been shown to mediate the gravity-dependent bone
formation and maintenance of bone structure [2].  Moreover, fluid shear stress by cultured
medium on osteoblasts induces expression of cyclooxygenase (COX)-2, the rate-limiting
enzyme for PG biosynthesis [3].  Furthermore, the serum-dependent COX-2 induction in
osteoblasts is suppressed significantly when cells are placed under microgravity in a space
shuttle [4].  These results demonstrate that the gravity-dependent COX-2 induction is
required for the bone tissue homeostasis.  However, it has not been investigated whether a
gravitational loading induces COX-2 in other tissues than bone.
Under the normal gravity, COX-2 is induced essentially in inflammatory lesions and
tumor tissues, which plays a key role in the respective pathological conditions [5-7].
Although cytokines and tumor promoters mediate COX-2 induction in these lesions, direct
mechanical stress also induces COX-2 in normal tissues.  For example, increased inner
pressure in the bladder and glomeruli induce COX-2 expression in the bladder detrusor
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muscle and glomerular podocytes, respectively [8, 9].  Moreover, fluid shear stress and
increased luminal pressure of vessels induce expression of COX-2 in the vessel walls [10-
12].  Accordingly, it is possible that mechanical stimuli caused by gravitational force
stimulate COX-2 expression in other tissues than bone, and affect their physiological
functions.
To assess this possibility, we examined the mRNA levels for COX-2 in various
tissues after exposing mice to hypergravity at 2G or 3G for 4 hours.  We demonstrate here
that hypergravity induces COX-2 expression in the lung, brain and heart.  In the heart,
expression of hypoxia-inducible factor (HIF)-1α and its downstream genes were
upregulated by hypergravity in a COX-2-dependent manner.  It has been reported recently
that inhibition of COX-2 in the heart causes increased risks of myocardial infarction and
stroke [13-16].  Moreover, COX-2 is induced by mild ischemia in the heart, and plays a
protective role against ischemic stress [17, 18].  Accordingly, our results suggest that the
hypergravity-dependent COX-2 expression in the heart has cardioprotective effects against
possible ischemic stress under hypergravity.
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Materials and methods
Animals  Female COX-2 (−/−) mice (n=3) and wild-type littermates (n=6) at 20
weeks of age were used for each hypergravity experiment at 2G, 3G and control 1G.
Generation of COX-2 gene knockout mice was described previously [6].  Animal
experiments were carried out with ethical committee approvals at Kyoto University (Kyoto,
Japan) and Japan Aerospace Exploration Agency (JAXA, Tsukuba, Japan).
Centrifugation Experiments  Mice were subjected to hypergravity for 4 hours using
Centrifugal Acceleration Test Facility at JAXA.  Centrifugation with a 7.25 m-arm at
15.70 rpm and 19.23 rpm produced 2G and 3G hypergravity conditions, respectively.  A
cage-mounting module was attached at the end of the arm that allowed one degree freedom,
thereby ensuring that the net G field was perpendicular to the cage floor.  Temperature and
moisture in the cages were maintained at 22.5 0C and 42 ± 2%, respectively.
Reverse-Transcription Polymerase Chain Reaction (RT-PCR)  Mice were euthanized
immediately after centrifugation, and tissue samples were collected in RNAlater solution
(Qiagen).  Total RNA was extracted from the colon, small intestine, stomach, kidney, lung,
brain, and heart using ISOGEN solution (Nippon Gene, Tokyo, Japan).  To determine the
expression levels of genes, extracted RNA was reverse-transcribed and amplified with PCR
using specific primers.  The genes analyzed were for COX-1, COX-2, HIF-1α, inducible
nitric oxide synthase (iNOS), vascular endothelial growth factor (VEGF), and heme
oxygenase (HO)-1.  The following primer sets were used for the respective genes: COX-1
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(F-5’-GAGATGCGCCTACAGCCCTT-3’, and R-5’-GCGTCTCACTAAGACAGACC-3’);





iNOS (F-5’-TGTCAGTGGCTTCCAGCTCC-3’, and R-5’-
TAGTCTTCCACCTGCTCCTC-3’); VEGF (F-5’-GCCAAGTGGTCCCAGGCTGC-3’,
and R-5’-CTGTGCTGTAGGAAGCTCAT-3’); and HO-1 (F-5’-
TGAGCTGTTTGAGGAGCTGCA-3’, and R-5’-GAAACGGATATCAAAGTGGCC-3’).
Specific GAPDH primers were used for the internal control to normalize the sample cDNA
amounts.  Band intensities of the RT-PCR products were quantified using Image J
application (NIH).  Statistical analyses were carried out by Student’s T-test, and p-values <
0.05 were considered as significant.
Immunohistochemistry  Localization of COX-1 and COX-2 in the heart was
investigated by immunohistochemistry.  The heart tissues were fixed in 4%
paraformaldehyde, embedded in paraffin wax, and sectioned at 4-µm thickness.  Sections
were microwave-treated to retrieve antigens, blocked with 10% goat serum, and incubated
with the primary antibodies.  Rabbit polyclonal antibodies for COX-1 (Santa Cruz
Biotechnology) and COX-2 (Cayman Chemical) were used at 100- and 500-fold dilutions,
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respectively.  Staining signals were visualized using Vectorstain Elite Kit (Vector)
according to the manufacturer’s protocol.  Serial sections were stained with hematoxylin
and eosin (H&E) and examined histologically.
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Results and Discussion
We first examined expression of COX-2 under normal gravity (1G) by RT-PCR in the
colon, small intestine, stomach, kidney, lung, brain and heart (Fig. 1A).  The COX-2
mRNA was detected in most tissues examined, which is consistent with a previous report
[19].  However, COX-2 expression was detected only weakly in the heart.  When mice
were placed under the 3G condition for 4 hours, the COX-2 mRNA level was increased
significantly in the lung, brain and heart, although it remained unchanged in other tissues
(Fig. 1A).  We then quantified band intensities of the RT-PCR products from the lung, brain
and heart of both 2G- and 3G-exposed mice, and determined the relative mRNA levels to
that of the 1G-control (Fig. 1B).  In the lung and brain, the COX-2 mRNA levels were
increased approximately 1.5 times both at 2G and 3G.  In the heart, however, COX-2
expression was markedly elevated to 2.5 and 2.8 times in the 2G- and 3G-exposed mice,
respectively.  It is likely that hypergravity at 2G is strong enough for the maximum COX-2
induction in these tissues, because the COX-2 level at 3G was almost the same as that at 2G.
While the direct metabolite of arachidonic acid by COX-2 is PGH2, it is further converted to
PGE2 by an inducible enzyme mPGES-1 that appears to be functionally coupled with COX-
2 [20].  Moreover, we have demonstrated recently that simultaneous expression of COX-2
and mPGES-1 in vivo results in elevated tissue PGE2 levels [21].  Interestingly, the levels
of mPGES-1 mRNA in the heart and brain were significantly higher under hypergravity than
those at 1G (Fig. 1C).  Accordingly, it is likely that hypergravity enhances PGE2 production
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in the heart and brain through simultaneous induction of both COX-2 and mPGES-1.
Accumulating evidence indicates that COX-2 plays a protective role in the heart from
infarction and stroke (ref. 20 and see below).  Accordingly, we examined heart samples for
further analyses.  First, we determined COX-2-expressing cells in the heart by
immunohistochemistry.  In the 3G-exposed mouse heart, a strong immunostaining signal
for COX-2 was found in the vessel wall (Fig. 2B), while it was not detected in the 1G-
control mice (Fig. 2A).  Abundant COX-2 staining in the 3G-exposed mouse heart was
found both in the vascular smooth muscle cells and endothelial cells (Fig. 2B, inset).  We
did not find any histopathological lesions in the heart of the 3G-exposed mice, when
compared with that of the control mice (Fig. 2C and D).  It has been reported that not only
COX-2, but also COX-1 is induced in the vessel walls, either by the increased fluid shear
stress or increased intraluminal pressure [11, 12], although COX-1 is generally expressed
constitutively.  To examine the possibility whether shear stress or increased luminal
pressure of the heart vessels was involved in the hypergravity-dependent COX-2 induction,
we determined expression of COX-1 in the heart by immunohistochemistry.  Notably, a
stronger signal for COX-1 was detected in the vessel wall of the 3G-exposed mouse heart
than in the 1G-control heart vessel (Fig. 2E and F).  Consistent with the immunostaining
results, the COX-1 mRNA level determined by RT-PCR was increased 1.9- and 1.8-fold in
the 2G- and 3G-exposed mouse heart, respectively (Fig. 3).  Induction of both COX
enzymes in the vessel walls strongly suggest that shear stress or increased inner pressure of
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the vessels stimulates COX-2 expression [11, 12].  It is possible that hemodynamic changes
under hypergravity increased blood volume in the heart vessels, causing shear stress and
increased pressure.  Importantly, induction of COX-1 in the heart was independent of
COX-2 expression, because the same induction of COX-1 was found in the COX-2 (−/−)
mouse heart under 2G and 3G conditions (Fig. 3).
Recently, it has been reported that users of high-dose rofecoxib (Vioxx), a COX-2
selective inhibitor, were 1.7 times more likely than non-users to have coronary heart disease
[13], and that long term use of rofecoxib increased risk of myocardial infarction and stroke
[15, 16].  One of the possible reasons for the heart problems by COX-2 inhibition is
thrombosis by suppressing COX-2-dependent PGI2 synthesis in the endothelial cells [10, 22].
PGI2 potently inhibits aggregation of platelets through vasodilation and preventing the
proliferation of vascular smooth muscle cells.  On the other hand, it has been demonstrated
that COX-2 expression and subsequent PGE2 production are induced in the heart during
ischemic preconditioning which is an adaptive response of the heart to a mild ischemic stress
and plays a key role for cardioprotection against myocardial infarction [17, 18, 23].  To
examine whether hypergravity-induced COX-2 expression contributes to cardioprotection
from ischemic stress, we analyzed expression of HIF-1α in the hypergravity-exposed mouse
heart (Fig. 3).  It has been shown that COX-2 induces HIF-1α at both transcriptional and
post-transcriptional levels [24, 25].  Interestingly, HIF-1α expression was elevated
significantly in the heart both at 2G and 3G.  Importantly, such induction of HIF-1α was not
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found in the COX-2 (−/−) mouse heart under the same conditions, indicating that COX-2 is
responsible for HIF-1α induction in the heart under hypergravity.  We thus determined
expression of HIF-1α target genes, vascular endothelial growth factor (VEGF), inducible
nitric oxide synthase (iNOS) and heme oxygenase (HO)-1, which may protect heart tissues
from ischemia by stimulating angiogenesis and production of vasodilators [26].  Notably,
expression was increased significantly for iNOS, VEGF and HO-1 in the 2G- and 3G-exposed
mouse heart, compared with that of the 1G-control (Fig. 3).  Furthermore, none of these
genes was upregulated in the COX-2 (−/−) mouse heart (Fig. 3).  These results, taken
together, indicate that hypergravity stimulates COX-2 expression in the heart vessels, which is
responsible for further induction of HIF-1α and downstream iNOS, VEGF and HO-1.  It is
of great interest to investigate whether these hypoxia-inducible factors are also induced in the
preconditioned heart in a COX-2-dependent manner [17, 18, 23].  Notably, COX-1
expression did not compensate for induction of these genes under hypergravity.  Because
mPGES-1 is functionally coupled with COX-2, induction of COX-1 may result in production
of other prostanoid than PGE2.  It has been demonstrated that COX-1 (−/−) mice show
increased cardiac ischemic/reperfusion injury (21).  Therefore, it is possible that COX-1 is
involved in the ischemic preconditioning through a PGE2/HIF-1α-independent pathway.
Although short term ischemic stress caused by coronary occlusion induces COX-2 in
the rabbit and mouse heart [18, 23], such ischemic stress is unlikely under the 2G or 3G
hypergravity.  Consistently, hypoxic signs such as necrosis were never found in the 3G-
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exposed mouse heart (Fig. 2D).  These results rule out the possiblity that COX-2 is induced
by ischemic stress under hypergravity.  Rather, it is likely that blood stream in the coronary
vessels is increased under hypergravity, causing the COX-2 induction described above.
Importantly, we did not find any histopathological lesions in the lung, brain or heart of
COX-2 (−/−) mice (data not shown).  It is possible that hypergravity per se is not the direct
cause of tissue hypoxia, but such hypergravitational responses rather help prevent
myocardial infarction and stroke from possible subsequent ischemic stresses.  Astronauts
are exposed to hypergravity at launch and aviators of jet fighters also experience sustained
gravitational forces.  Under such circumstances, aviators’ blood is pushed downwards, and
it is therefore possible that oxygen supply to the heart muscle falls less than the demand.
Induction of COX-2 can play a protective role in such situations.  Therefore, our results
caution the possibility that use of the COX-2 inhibitors and non-steroidal anti-inflammatory
drugs under hypergravity increase the risk for myocardial infarctions and strokes.
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Figure Legends
Fig. 1. Expression of COX-2 at indicated gravitational conditions.  (A) Representative RT-
PCR at 1G control (-) and 3G (+) in the colon, small intestine, stomach, kidney, lung, brain
and heart.  (B, C) Relative mRNA levels of COX-2 (B) and mPGES-1 (C) in the lung, brain
and heart at 2G and 3G, compared with that at 1G are presented as the mean ± s.d.  *, p <
0.05 to 1G control.
Fig. 2. Immunohistochemistry of COX-2 in the heart under 1G control (A) and 3G (B).
Inset in (B) shows the heart vessels at a higher magnification.  Near by serial sections of
(A) and (B) are shown in (C) and (D), respectively (H&E).  Immunostaining for COX-1 in
the heart at 1G (E) and 3G (F) are indicated.  Asterisks indicate vessels.  Arrowheads in
(B) and in (F) show positive staining for COX-2 and COX-1, respectively.  Arrows in the
inset (B) point to endothelial cells and smooth muscle cells that express COX-2.
Expression of COX-2 is not detected in the 1G-control heart vessels (A), whereas weak
COX-1 staining is found in the control vessel (E).  Bars indicate 200 µm.
Fig. 3. Expression of COX-1, HIF-1α, iNOS, VEGF and HO-1 at 2G and 3G compared
with that at 1G in the heart of the COX-2 wild-type mice (open bars) and COX-2 (−/−)
mice (black bars).  The relative mRNA levels are presented as the mean ± s.d.  *, p <
0.05 to 1G control of the respective COX-2 genotypes.



